Inogen (INGN)
Market Price (6/2/2026): $6.09 | Market Cap: $166.4 MilSector: Health Care | Industry: Life Sciences Tools & Services
Inogen (INGN)
Market Price (6/2/2026): $6.09Market Cap: $166.4 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -56% Low stock price volatilityVol 12M is 45% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Wearable Health Devices, and Geriatric Care. | Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -130% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.1% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2% Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.9% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% Key risksINGN key risks include [1] production-halting supply chain and manufacturing challenges stemming from component shortages and [2] adverse changes to crucial reimbursement policies, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -56% |
| Low stock price volatilityVol 12M is 45% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Wearable Health Devices, and Geriatric Care. |
| Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -130% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.1% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Key risksINGN key risks include [1] production-halting supply chain and manufacturing challenges stemming from component shortages and [2] adverse changes to crucial reimbursement policies, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Inogen (INGN) stock has remained largely at the same level since 2/28/2026 because of the following key factors:
1. Mixed Q1 2026 Financial Performance: Inogen reported Q1 2026 revenue of $85.1 million, surpassing analysts' estimates by 3.34% and representing a 3.4% increase year-over-year. However, this revenue beat was overshadowed by widening losses, with a GAAP net loss of $8.3 million (up from $6.2 million in Q1 2025) and an adjusted net loss of $4.0 million (up from $2.9 million in Q1 2025). Adjusted EBITDA also turned negative, registering a loss of $1.4 million compared to a positive $0.04 million in the prior-year period, primarily due to increased investments in research and development. This mixed financial report, combining revenue growth with deteriorating profitability, contributed to a neutral investor sentiment and limited significant stock movement.
2. Divergent Sales Trends in Key Markets: The company experienced contrasting performance across its markets. International sales of portable oxygen concentrators (POCs) were a significant strength, growing by 18% year-over-year, further bolstered by a positive foreign exchange impact of 460 basis points on total revenue. Conversely, these gains were largely offset by declines in U.S. sales and rentals, which faced pressures from ongoing channel mix shifts. This imbalance, where international growth mitigated domestic challenges, resulted in an overall largely stable, rather than growing, revenue picture for the period.
Show more
Stock Movement Drivers
Fundamental Drivers
The -0.2% change in INGN stock from 2/28/2026 to 6/1/2026 was primarily driven by a -0.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6012026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.10 | 6.09 | -0.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 349 | 351 | 0.8% |
| P/S Multiple | 0.5 | 0.5 | -0.5% |
| Shares Outstanding (Mil) | 27 | 27 | -0.5% |
| Cumulative Contribution | -0.2% |
Market Drivers
2/28/2026 to 6/1/2026| Return | Correlation | |
|---|---|---|
| INGN | -0.2% | |
| Market (SPY) | 10.9% | 22.4% |
| Sector (XLV) | -7.3% | 25.6% |
Fundamental Drivers
The -14.0% change in INGN stock from 11/30/2025 to 6/1/2026 was primarily driven by a -14.3% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6012026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.08 | 6.09 | -14.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 347 | 351 | 1.3% |
| P/S Multiple | 0.6 | 0.5 | -14.3% |
| Shares Outstanding (Mil) | 27 | 27 | -0.9% |
| Cumulative Contribution | -14.0% |
Market Drivers
11/30/2025 to 6/1/2026| Return | Correlation | |
|---|---|---|
| INGN | -14.0% | |
| Market (SPY) | 11.6% | 18.1% |
| Sector (XLV) | -5.4% | 21.9% |
Fundamental Drivers
The -5.2% change in INGN stock from 5/31/2025 to 6/1/2026 was primarily driven by a -7.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6012026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.42 | 6.09 | -5.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 340 | 351 | 3.4% |
| P/S Multiple | 0.5 | 0.5 | -0.5% |
| Shares Outstanding (Mil) | 25 | 27 | -7.9% |
| Cumulative Contribution | -5.2% |
Market Drivers
5/31/2025 to 6/1/2026| Return | Correlation | |
|---|---|---|
| INGN | -5.2% | |
| Market (SPY) | 30.2% | 29.9% |
| Sector (XLV) | 13.4% | 29.9% |
Fundamental Drivers
The -42.2% change in INGN stock from 5/31/2023 to 6/1/2026 was primarily driven by a -27.9% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6012026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.53 | 6.09 | -42.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 369 | 351 | -4.7% |
| P/S Multiple | 0.7 | 0.5 | -27.9% |
| Shares Outstanding (Mil) | 23 | 27 | -15.8% |
| Cumulative Contribution | -42.2% |
Market Drivers
5/31/2023 to 6/1/2026| Return | Correlation | |
|---|---|---|
| INGN | -42.2% | |
| Market (SPY) | 88.6% | 26.6% |
| Sector (XLV) | 21.6% | 24.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INGN Return | -24% | -42% | -72% | 67% | -27% | -3% | -85% |
| Peers Return | 29% | -24% | 1% | 37% | 7% | -10% | 32% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| INGN Win Rate | 58% | 33% | 33% | 50% | 42% | 60% | |
| Peers Win Rate | 54% | 46% | 54% | 50% | 62% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| INGN Max Drawdown | -64% | -46% | -84% | -38% | -54% | -24% | |
| Peers Max Drawdown | -22% | -41% | -42% | -27% | -34% | -16% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RMD, GTLS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/1/2026 (YTD)
How Low Can It Go
| Event | INGN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -48.2% | -9.5% |
| % Gain to Breakeven | 93.1% | 10.5% |
| Time to Breakeven | 105 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -28.2% | -33.7% |
| % Gain to Breakeven | 39.3% | 50.9% |
| Time to Breakeven | 5 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -15.5% | -3.7% |
| % Gain to Breakeven | 18.4% | 3.9% |
| Time to Breakeven | 7 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -41.0% | -12.2% |
| % Gain to Breakeven | 69.6% | 13.9% |
| Time to Breakeven | 62 days | 62 days |
In The Past
Inogen's stock fell -3.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | INGN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -48.2% | -9.5% |
| % Gain to Breakeven | 93.1% | 10.5% |
| Time to Breakeven | 105 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -28.2% | -33.7% |
| % Gain to Breakeven | 39.3% | 50.9% |
| Time to Breakeven | 5 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -41.0% | -12.2% |
| % Gain to Breakeven | 69.6% | 13.9% |
| Time to Breakeven | 62 days | 62 days |
In The Past
Inogen's stock fell -3.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Inogen (INGN)
AI Analysis | Feedback
Here are 1-3 brief analogies for Inogen:
Dexcom for respiratory conditions.
ResMed for portable oxygen concentrators.
Theragun for personalized respiratory devices.
AI Analysis | Feedback
```html- Inogen One: A portable device that concentrates ambient air to provide a single source of supplemental oxygen to patients.
- Inogen At Home: Stationary oxygen concentrators designed for home use.
- Inogen Tidal Assist Ventilators: Devices that assist patients with their breathing.
- Related accessories: Various accessories that complement their oxygen concentrators and ventilators.
- Product Rentals: A service allowing patients to rent their oxygen concentrators and related products directly from the company.
AI Analysis | Feedback
Inogen (INGN) primarily serves individual patients through various channels, and its major customer categories can be identified as:
- Patients: Individuals suffering from chronic respiratory conditions who require supplemental long-term oxygen therapy. Patients can directly purchase or rent Inogen's portable oxygen concentrators and related accessories.
- Healthcare Providers (Physicians and Other Clinicians): This category includes doctors, respiratory therapists, clinics, hospitals, and durable medical equipment (DME) providers. These entities either prescribe Inogen's products, recommend them to their patients, or purchase devices for direct provision to their patient base or for use within clinical settings.
- Third-Party Payors: These are organizations such as private health insurance companies, Medicare, Medicaid, and other government or managed care programs. They are crucial customers as they cover or reimburse the cost of Inogen's oxygen therapy products for eligible patients.
AI Analysis | Feedback
nullAI Analysis | Feedback
Kevin R.M. Smith, Chief Executive Officer, President and Director
Kevin R.M. Smith joined Inogen in November 2023. Prior to Inogen, he served as CEO, President, and Executive Director at Sirtex Medical Limited, a medical device company, from 2019 to 2023, and as Executive Vice President of Sales & Marketing, Americas at Sirtex from 2017 to 2019. He also held interim President, CEO, and Director roles at OncoSec Medical, Inc., a biotechnology company, from 2021 to 2022. His experience also includes leadership positions at Gel-e, Inc., Sensium Healthcare, and Teleflex, as well as various sales and marketing roles within the medical device industry.
Michael Bourque, Executive Vice President, Chief Financial Officer
Michael Bourque joined Inogen as Executive Vice President, Chief Financial Officer in March 2024. Before Inogen, he served as CFO and Treasurer of Chase Corporation, a global specialty chemicals company, from 2021 to 2023. Chase Corporation was acquired by KKR & Co. Inc. He also held the position of Chief Financial Officer at Keystone Dental, Senior Vice President, Chief Financial Officer and Treasurer at Analogic Corporation from 2014 to 2018, and Vice President of Finance for Axcelis Technologies from 2011 to 2014.
Adrien Mithalal, President, PhysioAssist organization
Adrien Mithalal joined Inogen in September 2023 following the acquisition of PhysioAssist. He served as President of the PhysioAssist organization for 12 years, where he led the development, industrialization, and marketing of the Simeox product. During his tenure, he brought in investors Mérieux Equity Partners and Turennes Capital. He has extensive experience in medical device development, certification, and market development within respiratory care.
Gregoire Ramade, Senior Vice President, Chief Commercial Officer (prior role at Vapotherm)
Gregoire Ramade joined Inogen in November 2023. Previously, he was with Vapotherm from May 2016 to October 2023, initially as Vice President, International, and later promoted to Senior Vice President and Chief Commercial Officer in September 2020. He also served as Vice President of Global Marketing and Business Development at Becton Dickinson Medical-Pharmaceutical Systems from January 2013 to May 2016, and held marketing leadership roles at Philips Healthcare and Philips Respironics.
Krishna Jhaveri, Chief Medical Officer
Krishna Jhaveri joined Inogen in February 2023. In her role, she has been responsible for defining the medical strategy for innovation projects, establishing the product safety team, improving processes and efficiencies, and crafting the company's claims strategy. She brings over ten years of experience in research, clinical development, medical affairs, regulatory affairs, product launches, and pharmacovigilance across the medical device and biopharmaceutical sectors.
AI Analysis | Feedback
Here are the key risks to Inogen's business:
- Changes in Reimbursement and Healthcare Policies: Inogen's revenue generation, particularly from rentals, is significantly impacted by changes in reimbursement rates and healthcare policies from Medicare, Medicaid, and private payors. Reductions in coverage or payment rates for oxygen therapy products could materially and adversely affect the company's financial performance. For instance, Inogen anticipates lower U.S. rental revenue in the first quarter and full year 2026 due to changes in reimbursement mix and reduced patients on service.
- Intense Competition and Rapid Technological Change: The portable oxygen concentrator market is highly competitive, with established players and new technologies constantly emerging. Inogen faces competition from larger corporations such as Koninklijke Philips N.V., Chart Industries, and Invacare Corporation. The company's competitive advantage could be eroded if rivals introduce more economically viable or technologically superior products, particularly concerning battery efficiency, size, and noise reduction. Failure to continuously innovate and successfully launch new products could negatively impact its market position.
- Regulatory Compliance and Product Liability: As a medical technology company, Inogen is subject to extensive governmental regulations, including those from the U.S. Food and Drug Administration (FDA) and European Medical Device Regulation (EU MDR). Non-compliance with these regulations could lead to severe penalties, product recalls, or limitations on its ability to market and sell products. Additionally, the risk of product liability claims is inherent in the medical device industry, which could result in significant financial and reputational damage.
AI Analysis | Feedback
nullAI Analysis | Feedback
Inogen (symbol: INGN) operates in the medical technology sector, focusing on respiratory care products. The addressable markets for their main products are global:
- Portable Oxygen Concentrators: The global portable oxygen concentrators market size is valued at approximately USD 2.14 billion in 2025 and is projected to increase to about USD 4.89 billion by 2035.
- Stationary Oxygen Concentrators: The global stationary oxygen concentrators market size was valued at USD 1.8 billion in 2024, poised to grow to USD 1.93 billion in 2025, and is expected to reach USD 3.37 billion by 2033.
- Tidal Assist Ventilators: These products fall within the broader global ventilators market, which was valued at USD 8.21 billion in 2025 and is projected to grow to USD 13.73 billion by 2034.
AI Analysis | Feedback
Inogen (INGN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Expansion into New Therapeutic Areas with New Product Launches: Inogen is broadening its product portfolio beyond portable oxygen concentrators (POCs) by introducing new devices and entering new markets. This includes the launch of the Voxi 5 stationary oxygen concentrator, which expands its market potential for long-term care patients in the U.S.. Additionally, the company is diversifying into airway clearance with the Simeox device, which has seen a limited market release in the U.S. and is nearing a commercial launch in China. A significant expansion is also underway with the introduction of Aurora CPAP masks for obstructive sleep apnea, marking Inogen's entry into the sleep therapy market and expanding its estimated total addressable market (TAM) from approximately $400 million to over $3 billion.
- International Market Growth and Geographic Expansion: International expansion is a central component of Inogen's long-term growth strategy, with strong year-over-year growth observed in international business. The company's partnership for entry into the Chinese COPD market is viewed as a substantial long-term growth opportunity, given its large size compared to the United States market. The anticipated commercial launch of the Simeox device in China, following a nearing completion clinical study, further underscores this international focus.
- Increased Adoption and Conversion to Portable Oxygen Concentrators (POCs): Continued demand for Inogen's products and the ongoing market trend of patients converting from traditional portable oxygen tanks to POCs are expected to contribute to revenue growth. This shift towards POCs, particularly within business-to-business channels, is seen as a favorable trend for the company's revenue prospects.
- Enhanced Sales Channel Effectiveness and Productivity: Inogen is focusing on optimizing its commercial investments and driving sales representative productivity across both its direct-to-consumer and business-to-business sales channels. Improvements in the efficiency and effectiveness of these sales teams are anticipated to lead to increased sales volume and overall revenue growth.
AI Analysis | Feedback
Share Repurchases
- In February 2026, Inogen announced that its Board of Directors authorized a share repurchase program of up to $30 million.
- The program is set to be executed before December 31, 2027, or until the maximum authorized amount is utilized.
- This repurchase program is intended to be financed through cash flow and existing cash reserves, reflecting confidence in the company's financial health and strategic direction.
Share Issuance
- Inogen's shares outstanding increased by 0.3% in Q4 2025 compared to the prior quarter, totaling 27 million shares.
Outbound Investments
- In September 2023, Inogen completed the acquisition of Physio-Assist SAS, thereby adding the Simeox airway clearance device to its product portfolio.
- In January 2025, Inogen announced a strategic collaboration with Yuwell Medical to expand its product offerings through distribution, engage in joint research and development, and accelerate its entry into the Chinese market.
- The company has focused on product diversification, launching new offerings such as the Voxi 5 stationary oxygen concentrator, Aurora CPAP masks for sleep apnea, and a digital health portal.
Capital Expenditures
- Inogen invested $979K in capital expenditures during Q4 2025.
- For the full year 2025, capital expenditures consumed a significant portion of operating cash flow, resulting in -$13.7 million in free cash flow, indicating heavy capital investment.
- Capital expenditures are primarily directed towards strengthening the core business, enhancing infrastructure, boosting commercial capabilities, accelerating innovation, and diversifying the product portfolio.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Inogen Earnings Notes | 12/16/2025 | |
| How Low Can Inogen Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 186.44 |
| Mkt Cap | 9.9 |
| Rev LTM | 4,147 |
| Op Inc LTM | 525 |
| FCF LTM | 10 |
| FCF 3Y Avg | 136 |
| CFO LTM | 105 |
| CFO 3Y Avg | 249 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.4% |
| Rev Chg 3Y Avg | 11.3% |
| Rev Chg Q | 3.4% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Inc Chg LTM | 5.9% |
| Op Inc Chg 3Y Avg | 19.6% |
| Op Mgn LTM | 12.7% |
| Op Mgn 3Y Avg | 13.8% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 2.5% |
| CFO/Rev 3Y Avg | 6.0% |
| FCF/Rev LTM | 0.2% |
| FCF/Rev 3Y Avg | 3.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 9.9 |
| P/S | 2.4 |
| P/Op Inc | 14.1 |
| P/EBIT | 14.1 |
| P/E | -6.7 |
| P/CFO | 14.3 |
| Total Yield | -0.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.1% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.8% |
| 3M Rtn | -1.5% |
| 6M Rtn | -12.4% |
| 12M Rtn | -5.2% |
| 3Y Rtn | -13.0% |
| 1M Excs Rtn | -18.0% |
| 3M Excs Rtn | -11.9% |
| 6M Excs Rtn | -26.0% |
| 12M Excs Rtn | -35.3% |
| 3Y Excs Rtn | -97.6% |
Price Behavior
| Market Price | $6.09 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 02/14/2014 | |
| Distance from 52W High | -32.0% | |
| 50 Days | 200 Days | |
| DMA Price | $6.63 | $7.03 |
| DMA Trend | indeterminate | up |
| Distance from DMA | -8.2% | -13.4% |
| 3M | 1YR | |
| Volatility | 42.7% | 45.7% |
| Downside Capture | 132.95 | 124.66 |
| Upside Capture | 77.61 | 79.17 |
| Correlation (SPY) | 23.9% | 30.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.95 | 0.49 | 0.68 | 0.67 | 1.15 | 1.15 |
| Up Beta | 1.58 | -0.97 | -0.43 | 0.50 | 1.25 | 1.02 |
| Down Beta | 4.07 | 1.08 | 0.57 | 1.13 | 1.26 | 0.69 |
| Up Capture | -67% | 86% | 108% | 34% | 84% | 184% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 21 | 33 | 58 | 116 | 347 |
| Down Capture | 122% | 256% | 130% | 82% | 118% | 111% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 19 | 29 | 62 | 126 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INGN | |
|---|---|---|---|---|
| INGN | -4.7% | 45.5% | 0.03 | - |
| Sector ETF (XLV) | 13.7% | 14.6% | 0.66 | 29.6% |
| Equity (SPY) | 30.2% | 11.8% | 1.93 | 29.6% |
| Gold (GLD) | 34.7% | 26.7% | 1.09 | -3.9% |
| Commodities (DBC) | 42.7% | 18.9% | 1.75 | -11.0% |
| Real Estate (VNQ) | 9.6% | 13.2% | 0.44 | 13.6% |
| Bitcoin (BTCUSD) | -30.6% | 41.6% | -0.77 | 15.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INGN | |
|---|---|---|---|---|
| INGN | -37.1% | 61.3% | -0.50 | - |
| Sector ETF (XLV) | 5.2% | 14.7% | 0.17 | 29.4% |
| Equity (SPY) | 14.2% | 17.0% | 0.65 | 32.5% |
| Gold (GLD) | 18.5% | 18.0% | 0.83 | 1.9% |
| Commodities (DBC) | 10.3% | 19.4% | 0.42 | 2.7% |
| Real Estate (VNQ) | 2.8% | 18.8% | 0.05 | 30.7% |
| Bitcoin (BTCUSD) | 13.7% | 54.6% | 0.44 | 15.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INGN | |
|---|---|---|---|---|
| INGN | -18.1% | 56.8% | -0.11 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.47 | 29.5% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 31.8% |
| Gold (GLD) | 13.1% | 16.0% | 0.68 | 2.1% |
| Commodities (DBC) | 7.4% | 17.9% | 0.33 | 8.8% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 27.0% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | 94.00 Mil | 95.50 Mil | 97.00 Mil | ||||
| 2026 Revenue | 366.00 Mil | 369.50 Mil | 373.00 Mil | 0 | Affirmed | Guidance: 369.50 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 366.00 Mil | 369.50 Mil | 373.00 Mil | 3.9% | Higher New | Actual: 355.50 Mil for 2025 | |
| 2026 Revenue Growth | 6.0% | ||||||
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.